N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.

Despite recent therapeutic advances, prostate cancer remains a leading cause of cancer-related death. A subset of castration resistant prostate cancers become androgen receptor (AR) signaling-independent and develop neuroendocrine prostate cancer (NEPC) features through lineage plasticity. These NEPC tumors, associated with aggressive disease and poor prognosis, are driven, in part, by aberrant expression of N-Myc, through mechanisms that remain unclear. Integrative analysis of the N-Myc transcriptome, cistrome and interactome using in vivo, in vitro and ex vivo models (including patient-derived organoids) identified a lineage switch towards a neural identity associated with epigenetic reprogramming. N-Myc and known AR-co-factors (e.g., FOXA1 and HOXB13) overlapped, independently of AR, at genomic loci implicated in neural lineage specification. Moreover, histone marks specifically associated with lineage-defining genes were reprogrammed by N-Myc. We also demonstrated that the N-Myc-induced molecular program accurately classifies our cohort of patients with advanced prostate cancer. Finally, we revealed the potential for EZH2 inhibition to reverse the N-Myc-induced suppression of epithelial lineage genes. Altogether, our data provide insights on how N-Myc regulates lineage plasticity and epigenetic reprogramming associated with lineage-specification. The N-Myc signature we defined could also help predict the evolution of prostate cancer and thus better guide the choice of future therapeutic strategies.

[1]  T. Graeber,et al.  Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage , 2018, Science.

[2]  S. Begum,et al.  Sequence Alignment , 2018, Beginners Guide to Bioinformatics for High Throughput Sequencing.

[3]  T. Graeber,et al.  Re: A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers. , 2019, The Journal of urology.

[4]  Joshua M. Stuart,et al.  Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Dong Gao,et al.  Patient derived organoids to model rare prostate cancer phenotypes , 2018, Nature Communications.

[6]  Zhiguo Zhang,et al.  Asf1a resolves bivalent chromatin domains for the induction of lineage-specific genes during mouse embryonic stem cell differentiation , 2018, Proceedings of the National Academy of Sciences.

[7]  Zhihua Liu,et al.  Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 , 2018, Proceedings of the National Academy of Sciences.

[8]  Joshua M. Stuart,et al.  Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. , 2018, Cell.

[9]  Ryan D. Chow,et al.  Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity. , 2018, Developmental cell.

[10]  D. Rickman,et al.  The Expanding World of N-MYC-Driven Tumors. , 2018, Cancer discovery.

[11]  Donald R. Polaski,et al.  Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma , 2018, Nature Genetics.

[12]  D. Rickman,et al.  Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle , 2017, Cell reports.

[13]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[14]  Dong Chen,et al.  Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis , 2017, Blood Cancer Journal.

[15]  Takafumi N. Yamaguchi,et al.  TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer , 2017, Nature Genetics.

[16]  M. Rubin,et al.  Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. , 2017, Cancer discovery.

[17]  M. Rubin,et al.  Biology and evolution of poorly differentiated neuroendocrine tumors , 2017, Nature Medicine.

[18]  Kristofer C. Berrett,et al.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. , 2017, Cancer cell.

[19]  K. Plath,et al.  Cbx3 maintains lineage specificity during neural differentiation. , 2017, Genes & development.

[20]  A. Brunet,et al.  Single-Cell Transcriptomic Analysis Defines Heterogeneity and Transcriptional Dynamics in the Adult Neural Stem Cell Lineage. , 2017, Cell reports.

[21]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[22]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[23]  M. Rubin,et al.  The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. , 2017, Cancer discovery.

[24]  U. Schüller,et al.  Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells , 2016, Oncotarget.

[25]  Kaitlyn M. Gayvert,et al.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.

[26]  E. Wolf,et al.  The ubiquitin ligase HUWE1 regulates hematopoietic stem cell maintenance and lymphoid commitment , 2016, Nature immunology.

[27]  J. Wolf,et al.  Different promoter affinities account for specificity in MYC-dependent gene regulation , 2016, eLife.

[28]  A. Gazdar,et al.  Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer , 2016, Genes & development.

[29]  Fidel Ramírez,et al.  deepTools2: a next generation web server for deep-sequencing data analysis , 2016, Nucleic Acids Res..

[30]  Joshua M. Stuart,et al.  N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. , 2016, Cancer cell.

[31]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[32]  J. Carroll,et al.  Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes , 2016, Nature Protocols.

[33]  Jindan Yu,et al.  FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression , 2016, Oncogene.

[34]  K. Baggerly,et al.  Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers , 2015, Clinical Cancer Research.

[35]  Henry W. Long,et al.  The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis , 2015, Nature Genetics.

[36]  Vladimir Vacic,et al.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.

[37]  P. Nelson,et al.  SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[38]  G. Getz,et al.  RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.

[39]  F. Westermann,et al.  A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies , 2014, Oncogene.

[40]  Ximing J. Yang,et al.  Neuroendocrine differentiation of prostate cancer: a review. , 2014, American journal of clinical and experimental urology.

[41]  Eugenia G. Giannopoulou,et al.  The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer , 2014, Nature Communications.

[42]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[43]  M. Kloor,et al.  Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases , 2014, Virchows Archiv.

[44]  Raluca Gordân,et al.  Sequence specificity incompletely defines the genome-wide occupancy of Myc , 2014, Genome Biology.

[45]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[46]  M. Rubin,et al.  Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.

[47]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[48]  W. Weiss,et al.  The prenatal origins of cancer , 2014, Nature Reviews Cancer.

[49]  C. Rudin,et al.  MYC, MAX, and small cell lung cancer. , 2014, Cancer discovery.

[50]  I. Huijbers,et al.  Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells , 2014, EMBO molecular medicine.

[51]  Wennuan Liu,et al.  Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.

[52]  D. Zheng,et al.  ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.

[53]  Gerald C. Chu,et al.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. , 2013, Cancer research.

[54]  M. Rubin,et al.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. , 2013, Neoplasia.

[55]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[56]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[57]  Herbert Waldmann,et al.  A framework for identification of actionable cancer genome dependencies in small cell lung cancer , 2012, Proceedings of the National Academy of Sciences.

[58]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[59]  P. Northcott,et al.  Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. , 2012, Cancer cell.

[60]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[61]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[62]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[63]  Andrew E. Jaffe,et al.  Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .

[64]  P. Troncoso,et al.  Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features , 2011, Clinical Cancer Research.

[65]  A. Ashworth,et al.  Molecular profiling reveals frequent gain of MYCN and anaplasia‐specific loss of 4q and 14q in wilms tumor , 2011, Genes, chromosomes & cancer.

[66]  M. Gerstein,et al.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.

[67]  R. M. Simpson,et al.  Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. , 2011, The American journal of pathology.

[68]  P. Troncoso,et al.  Neuroendocrine prostate cancer xenografts with large‐cell and small‐cell features derived from a single patient's tumor: Morphological, immunohistochemical, and gene expression profiles , 2011, The Prostate.

[69]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[70]  Chris Sander,et al.  MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors , 2011, PloS one.

[71]  A. Skoudy,et al.  Pancreatic Ductal Adenocarcinoma and Transcription Factors: Role of c-Myc , 2011, Journal of gastrointestinal cancer.

[72]  Edward L. Huttlin,et al.  A Tissue-Specific Atlas of Mouse Protein Phosphorylation and Expression , 2010, Cell.

[73]  C. Bieberich,et al.  MYC and Prostate Cancer. , 2010, Genes & cancer.

[74]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[75]  Aaron R. Quinlan,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[76]  Clifford A. Meyer,et al.  Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.

[77]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[78]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[79]  Jun Luo,et al.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.

[80]  T. Mikkelsen,et al.  Genome-scale DNA methylation maps of pluripotent and differentiated cells , 2008, Nature.

[81]  Georgia Panagiotakos,et al.  Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells , 2007, Nature Biotechnology.

[82]  K. Pienta,et al.  A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. , 2007, Molecular cell.

[83]  T. Mikkelsen,et al.  Genome-wide maps of chromatin state in pluripotent and lineage-committed cells , 2007, Nature.

[84]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[85]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[86]  David C. Corney,et al.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.

[87]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[88]  G. Grosveld,et al.  Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9. , 2005, Blood.

[89]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Yong-jie Lu,et al.  Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  R. Puri,et al.  Gene expression in human embryonic stem cell lines: unique molecular signature. , 2004, Blood.

[92]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[93]  M. Mann,et al.  Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. , 2003, Analytical chemistry.

[94]  K. Sayama,et al.  Different effects of dominant negative mutants of desmocollin and desmoglein on the cell-cell adhesion of keratinocytes. , 2000, Journal of cell science.

[95]  F. Davis,et al.  The conditional probability of survival of patients with primary malignant brain tumors , 1999, Cancer.

[96]  M. Cole,et al.  The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F Oncoproteins , 1998, Cell.

[97]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[98]  Mark L. Greenberg,et al.  MYCN gene amplification in rhabdomyosarcoma , 1994, Cancer.

[99]  T. Salmi,et al.  L-myc and N-myc in hematopoietic malignancies. , 1993, Leukemia & lymphoma.

[100]  K. Klempnauer,et al.  Sequence-specific DNA binding by Myc proteins. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[101]  R. Eisenman,et al.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.

[102]  M. Lohuizen,et al.  N‐myc is frequently activated by proviral insertion in MuLV‐induced T cell lymphomas. , 1989, The EMBO journal.

[103]  S. Baylin,et al.  Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. , 1986, Science.

[104]  J. Battey,et al.  Human small-cell lung cancers show amplification and expression of the N-myc gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[105]  J. Garson,et al.  N-MYC AMPLIFICATION IN MALIGNANT ASTROCYTOMA , 1985, The Lancet.

[106]  Wen-Hwa Lee,et al.  Expression and amplification of the N-myc gene in primary retinoblastoma , 1984, Nature.

[107]  McLellan Gh.  Letter: SI units. , 1975 .